955082-98-1

Basic information

• Product Name: (3R,4S)-3-fluoropiperidin-4-ol
• Synonyms: Cis-3-Fluoropiperidin-4-Ol;Cis-3-Fluoropiperidin-4-Ol(WX601314)
• CAS NO: 955082-98-1
• Molecular Formula: C5H10FNO
• Molecular Weight: 119.1374032
• Mol File: 955082-98-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3R,4S)-3-fluoropiperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-3-fluoropiperidin-4-ol(955082-98-1)
• EPA Substance Registry System: (3R,4S)-3-fluoropiperidin-4-ol(955082-98-1)

Safety Data

• Hazardous Substances Data: 955082-98-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
(3R,4S)-3-fluoropiperidin-4-ol is used as a building block in the development of pharmaceuticals due to its unique reactivity and physical properties. Its chiral nature and fluorine substitution may contribute to the compound's biological activity and pharmacological potential, making it a valuable component in the creation of new drugs.
Used in Agrochemical Development:
(3R,4S)-3-fluoropiperidin-4-ol is also used as a building block in the development of agrochemicals. Its unique properties and reactivity can be harnessed to create new compounds with potential applications in agriculture, such as pesticides or herbicides.
Used in Organic Synthesis:
As a fluorinated derivative of piperidin-4-ol, (3R,4S)-3-fluoropiperidin-4-ol is used in organic synthesis for the creation of various chemical compounds. Its specific stereochemistry and fluorine substitution make it a versatile and potentially valuable compound in multiple fields of chemistry.

Upstream product

• 1174020-40-6 (+)-(3S,4R)-3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 1174020-42-8 (-)-(3R,4S)-3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 1523530-55-3 rac cis-3-fluoropiperidin-4-ol hydrochloride 
• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 845256-59-9 benzyl 3-fluoro-4-oxopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 373604-28-5 3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 1209780-78-8 benzyl (3S,4S)-3-fluoro-4-((4-nitrobenzoyl)oxy)piperidine-1-carboxylate 

Relevant articles and documents

NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR

The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clinical responses only last for 8-14 months. Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel). Herein we describe how a noncovalent double mutant selective lead compound was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or reduction of three-dimensional character. Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom. Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.